Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin

被引:33
作者
Weiss, L
Slavin, S
机构
[1] Hadassah Univ Hosp, Dept Bone Marrow Transplant, Canc Immunotherapy Ctr, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Immunobiol Res Lab, IL-91120 Jerusalem, Israel
关键词
graft-versus-host disease; anti-CD4; anti-CD8; veto cells;
D O I
10.1038/sj.bmt.1701784
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Control of graft-versus-host disease (GVHD) post allogeneic spleen cell transplantation was partly achieved by administration of host-type lymphocytes, (C57BL/6 x BALB/c) F1 mice were conditioned by total body irradiation and transplanted with parental C57BL/6 spleen cells to induce severe GVHD, Infusion of mature host-type lymphocytes did not change the degree of chimerism but protected most of the recipients from lethal GVHD. Treatment of host-type blood cells with anti-CDS antibodies resulted in loss of the GVHD protective effects mediated by host cells, whereas after treatment of the host with anti-CD4 antibodies protective host cells given 4 days after induction of GVHD resulted in successful rescue of all transplanted recipients from lethal GVHD, Administration of host blood cells could effectively protect against GVHD induced by donor spleen cells and low-dose rIL-2. GVHD protection resulted from down-regulation of alloreactive donor T cells and not by rejection of GVHD effector cells, Taken together, administration of host hematopoietic cells particularly host CD8(+) T cells, may be considered for prevention or control of GVHD following allogeneic bone marrow transplantation, thus also explaining the increased resistance of mixed chimeras to GVHD.
引用
收藏
页码:1139 / 1143
页数:5
相关论文
共 25 条
[1]  
APPERLEY JF, 1986, BONE MARROW TRANSPL, V1, P53
[2]  
BACIGALUPO A, 1991, BLOOD, V77, P1423
[3]   ACTIVELY ACQUIRED TOLERANCE OF FOREIGN CELLS [J].
BILLINGHAM, RE ;
BRENT, L ;
MEDAWAR, PB .
NATURE, 1953, 172 (4379) :603-606
[4]  
Chiang KY, 1996, BONE MARROW TRANSPL, V17, P39
[5]  
COLLINS RH, 1992, BONE MARROW TRANSPL, V10, P391
[6]   PECULIAR IMMUNOBIOLOGY OF BONE MARROW ALLOGRAFTS .2. REJECTION OF PARENTAL GRAFTS BY RESISTANT F1 HYBRID MICE [J].
CUDKOWICZ, G ;
BENNETT, M .
JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 134 (06) :1513-+
[7]   BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE - INCREASED RISK FOR RELAPSE ASSOCIATED WITH T-CELL DEPLETION [J].
GOLDMAN, JM ;
GALE, RP ;
HOROWITZ, MM ;
BIGGS, JC ;
CHAMPLIN, RE ;
GLUCKMAN, E ;
HOFFMANN, RG ;
JACOBSEN, SJ ;
MARMONT, AM ;
MCGLAVE, PB ;
MESSNER, HA ;
RIMM, AA ;
ROZMAN, C ;
SPECK, B ;
TURA, S ;
WEINER, RS ;
BORTIN, MM .
ANNALS OF INTERNAL MEDICINE, 1988, 108 (06) :806-814
[8]  
HIGANO CS, 1990, TRANSPLANTATION, V50, P175
[9]  
HOROWITZ MM, 1990, BLOOD, V75, P555
[10]   RECONSTITUTION WITH SYNGENEIC PLUS ALLOGENEIC OR XENOGENEIC BONE-MARROW LEADS TO SPECIFIC ACCEPTANCE OF ALLOGRAFTS OR XENOGRAFTS [J].
ILDSTAD, ST ;
SACHS, DH .
NATURE, 1984, 307 (5947) :168-170